Research progress of Hemoporfin--part one: preclinical study

Yu Pu1, Wenhui Chen, Zhengwei Yu

  • 1R&D Center for Photodynamic Therapy Drug, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., No. 308, Cailun Rd., Shanghai 201210, PR China.

Summary

Hemoporfin, a second-generation photosensitizer, demonstrates excellent properties for photodynamic therapy (PDT). Preclinical studies confirm its optical characteristics, activity mechanisms, and safety profile for PDT applications.